DiaMedica Therapeutics Inc. (DMAC)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on marketable securities | -19 | |||
| Income tax expense | 6 | |||
| Research and development | 5,822 | |||
| General and administrative | 2,185 | |||
| Operating loss | -8,007 | |||
| Other income, net | 314 | |||
| Loss before income tax expense | -7,693 | |||
| Net loss | -7,699 | |||
| Net loss and comprehensive loss | -7,718 | |||
| Basic and diluted net loss per share (in dollars per share) | -0.18 | |||
| Weighted average shares outstandingbasic and diluted (in shares) | 42,957,619 | |||